DNABW (Ginkgo Bioworks Holdings) Revenue: $141.31 Mil (TTM As of Mar. 2026)


DNABW Ginkgo Bioworks Holdings Inc DNABW
61 GF Score
Price $0.00
! 5 Warning Signs
View Full Analysis

What is Ginkgo Bioworks Holdings Revenue?

Ginkgo Bioworks Holdings DNABW 61 Revenue is $141.31 Mil as of Mar. 2026. GuruFocus rates DNABW with a GF Score™ of 61/100. The stock has 5 warning signs investors should review.

Ginkgo Bioworks Holdings's revenue for the three months ended in Mar. 2026 was $19.47 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $141.31 Mil. Ginkgo Bioworks Holdings's Revenue per Share for the three months ended in Mar. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.

Warning Sign:

Ginkgo Bioworks Holdings Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Ginkgo Bioworks Holdings was -41.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was -35.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 64.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 7 years, Ginkgo Bioworks Holdings's highest 3-Year average Revenue per Share Growth Rate was 581.10% per year. The lowest was -35.40% per year. And the median was 170.70% per year.


Ginkgo Bioworks Holdings  (OTCPK:DNABW) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Ginkgo Bioworks Holdings Revenue Related Terms


Ginkgo Bioworks Holdings Revenue Historical Data

* Premium members only.

The historical data trend for Ginkgo Bioworks Holdings's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ginkgo Bioworks Holdings Revenue Chart

Ginkgo Bioworks Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial 313.84 477.71 251.46 227.04 170.16

Ginkgo Bioworks Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.23 49.60 38.84 33.40 19.47

DNABW vs AGMB, ACRS, RLMD: Revenue Comparison

For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ginkgo Bioworks Holdings Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Revenue distribution charts can be found below:

* The bar in red indicates where Ginkgo Bioworks Holdings's Revenue falls into.


DNABW
61GF Score
Ginkgo Bioworks Holdings Inc DNABW
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ginkgo Bioworks Holdings Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $141.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $141.31 Mil mean?
Ginkgo Bioworks Holdings (DNABW) has a Revenue of $141.31 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Ginkgo Bioworks Holdings and its competitors.
Is Ginkgo Bioworks Holdings' Revenue too high?
Ginkgo Bioworks Holdings' current Revenue is $141.31 Mil. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' Revenue compare to AGMB and ACRS?
Ginkgo Bioworks Holdings' Revenue of $141.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Ginkgo Bioworks Holdings and its competitors. Ginkgo Bioworks Holdings's current Revenue is $141.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Ginkgo Bioworks Holdings (DNABW) has a current Revenue of $141.31 Mil. The current Revenue is $141.31 Mil. Ginkgo Bioworks Holdings' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (DNABW), the current Revenue is $141.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ginkgo Bioworks Holdings Business Description

Other Exchanges DNA:USADNA:Mexico
Address 27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
61GF Score

Get the complete analysis for DNABW

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price